Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...

Full description

Saved in:
Bibliographic Details
Main Authors: Desirée Van Oorschot (Author), Anastassia Anastassopoulou (Author), Barbara Poulsen Nautrup (Author), Lijoy Varghese (Author), Alfred von Krempelhuber (Author), Mohamed Neine (Author), Stéphane Lorenc (Author), Desmond Curran (Author)
Format: Book
Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items